Blocking fatty acid oxidation by knocking out CPT1A/CPT2 via CRISPR-mediated has been shown to inhibit the invasive phenotype of radiotherapy-resistant breast cancer, suggesting that CPT2 is a potential metabolic target for breast cancer radiotherapy [66]. Here, CPT1A is linked to breast cancer.